155 related articles for article (PubMed ID: 22360696)
1. Cost burden and treatment patterns associated with management of heavy menstrual bleeding.
Jensen JT; Lefebvre P; Laliberté F; Sarda SP; Law A; Pocoski J; Duh MS
J Womens Health (Larchmt); 2012 May; 21(5):539-47. PubMed ID: 22360696
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of variation in heavy menstrual bleeding treatments by age and underlying cause.
Copher R; Le Nestour E; Law A; Pocoski J; Zampaglione E
Curr Med Res Opin; 2013 Feb; 29(2):127-39. PubMed ID: 23268728
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and healthcare resource utilization and costs in heavy menstrual bleeding: a Japanese claims database analysis.
Akiyama S; Tanaka E; Cristeau O; Onishi Y; Osuga Y
J Med Econ; 2018 Sep; 21(9):853-860. PubMed ID: 29770717
[TBL] [Abstract][Full Text] [Related]
4. Health Care Costs and Treatment Patterns Associated with Uterine Fibroids and Heavy Menstrual Bleeding: A Claims Analysis.
Wang A; Wang S; Owens CD; Vora JB; Diamond MP
J Womens Health (Larchmt); 2022 Jun; 31(6):856-863. PubMed ID: 34591695
[No Abstract] [Full Text] [Related]
5. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients.
Bickston SJ; Waters HC; Dabbous O; Tang BI; Rahman M
J Manag Care Pharm; 2008 May; 14(4):352-62. PubMed ID: 18500913
[TBL] [Abstract][Full Text] [Related]
6. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
[TBL] [Abstract][Full Text] [Related]
7. Employer-perspective cost comparison of surgical treatments for abnormal uterine bleeding.
Miller JD; Bonafede MM; Pohlman SK; Cholkeri-Singh A; Troeger KA
J Comp Eff Res; 2020 Jan; 9(1):67-77. PubMed ID: 31773992
[No Abstract] [Full Text] [Related]
8. Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population.
Furst DE; Clarke A; Fernandes AW; Bancroft T; Gajria K; Greth W; Iorga SR
J Med Econ; 2013; 16(4):500-9. PubMed ID: 23363329
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
11. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
[TBL] [Abstract][Full Text] [Related]
12. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E
Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Fuldeore M; Yang H; Du EX; Soliman AM; Wu EQ; Winkel C
Fertil Steril; 2015 Jan; 103(1):163-71. PubMed ID: 25455535
[TBL] [Abstract][Full Text] [Related]
14. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
16. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
[TBL] [Abstract][Full Text] [Related]
17. The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings.
Black J; Reaven NL; Funk SE; McGaughey K; Ohayon M; Guilleminault C; Ruoff C; Mignot E
Sleep Med; 2014 May; 15(5):522-9. PubMed ID: 24768358
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
19. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population.
Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT; Doshi JA
J Med Econ; 2014 Feb; 17(2):148-58. PubMed ID: 24168640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
